Suscripción a Biblioteca: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publicado 6 números por año

ISSN Imprimir: 0743-4863

ISSN En Línea: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Mucosal Immunization: A Review of Strategies and Challenges

Volumen 31, Edición 4, 2014, pp. 273-303
DOI: 10.1615/CritRevTherDrugCarrierSyst.2014010102
Get accessGet access

SINOPSIS

The vast majority of pathogens enter the human body via the mucosal surfaces of the gastrointestinal, respiratory, and urogenital tracts, where they initiate mucosal infections that lead to systemic infections. Despite strong evidence that a good mucosal immune response can effectively prevent systemic infection too, only a few mucosal vaccines are available due to their low efficiency. Most current immunization techniques involve systemic injection, but they are ineffective to induce immunization at a mucosal site. It is a great challenge to target a mucosal compartment that can induce protective immunity at mucosal sites as well as systemic sites. A better understanding of cellular and molecular factors involved in the regulation of mucosal immunity will aid in the design of safer mucosal vaccines that elicit the desired protective immunity against infectious diseases such as HIV. The development of mucosal vaccines, whether for prevention of infectious diseases or for immunotherapy, requires antigen delivery and adjuvant systems that can effectively present vaccine or immunotherapeutic antigens to the mucosal sites. In this review, we examine the mechanism of mucosal protection, induction of mucosal immune response, types of vaccines, current status of marketed vaccines, and novel strategies for protection against infections and for treatment of inflammatory disorders. Additionally, we offer perspectives on future challenges and research directions.

CITADO POR
  1. Gu Hongjing, Li Tieling, Han Lina, Zhu Ping, Zhang Peirui, Zhang Shaogeng, Sun Sujing, Duan Yueqiang, Xing Li, Zhao Zhongpeng, Lai Chengcai, Wen Bohai, Wang Xiliang, Yang PengHui, Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination, Human Vaccines & Immunotherapeutics, 11, 4, 2015. Crossref

  2. Nagatomo Daiki, Taniai Madoka, Ariyasu Harumi, Taniguchi Mutsuko, Aga Miho, Ariyasu Toshio, Ohta Tsunetaka, Fukuda Shigeharu, Cholesteryl Pullulan Encapsulated TNF-αNanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus, BioMed Research International, 2015, 2015. Crossref

  3. Salazar-González Jorge Alberto, González-Ortega Omar, Rosales-Mendoza Sergio, Gold nanoparticles and vaccine development, Expert Review of Vaccines, 14, 9, 2015. Crossref

  4. Navarro-Tovar Gabriela, Palestino Gabriela, Rosales-Mendoza Sergio, An overview on the role of silica-based materials in vaccine development, Expert Review of Vaccines, 15, 11, 2016. Crossref

  5. Tang Zeli, Shang Mei, Chen Tingjin, Ren Pengli, Sun Hengchang, Qu Hongling, Lin Zhipeng, Zhou Lina, Yu Jinyun, Jiang Hongye, Zhou Xinyi, Li Xuerong, Huang Yan, Xu Jin, Yu Xinbing, The immunological characteristics and probiotic function of recombinant Bacillus subtilis spore expressing Clonorchis sinensis cysteine protease, Parasites & Vectors, 9, 1, 2016. Crossref

  6. Tang Zeli, Sun Hengchang, Chen TingJin, Lin Zhipeng, Jiang Hongye, Zhou Xinyi, Shi Cunbin, Pan Houjun, Chang Ouqin, Ren Pengli, Yu Jinyun, Li Xuerong, Xu Jin, Huang Yan, Yu Xinbing, Oral delivery of Bacillus subtilis spores expressing cysteine protease of Clonorchis sinensis to grass carp ( Ctenopharyngodon idellus ): Induces immune responses and has no damage on liver and intestine function, Fish & Shellfish Immunology, 64, 2017. Crossref

  7. Khan Arshad, Singh Shailbala, Galvan Gloria, Jagannath Chinnaswamy, Sastry K., Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in Mice, Vaccines, 5, 4, 2017. Crossref

  8. Xu Bohui, Zhang Wenjing, Chen Yulin, Xu Yan, Wang Bo, Zong Li, Eudragit® L100-coated mannosylated chitosan nanoparticles for oral protein vaccine delivery, International Journal of Biological Macromolecules, 113, 2018. Crossref

  9. Sun Hengchang, Lin Zhipeng, Zhao Lu, Chen Tingjin, Shang Mei, Jiang Hongye, Tang Zeli, Zhou Xinyi, Shi Mengchen, Zhou Lina, Ren Pengli, Qu Honglin, Lin Jinsi, Li Xuerong, Xu Jin, Huang Yan, Yu Xinbing, Bacillus subtilis spore with surface display of paramyosin from Clonorchis sinensis potentializes a promising oral vaccine candidate, Parasites & Vectors, 11, 1, 2018. Crossref

  10. Nie Xubiao, Xie Rui, Tuo Biguang, Effects of Estrogen on the Gastrointestinal Tract, Digestive Diseases and Sciences, 63, 3, 2018. Crossref

  11. Yelyseyeva I. V., Babych Ye. M., Zhdamarova L. A., Belozersky V. I., Kolpak S. A., POSSIBLE WAYS TO IMPROVE THE SAFETY OF DIPHTHERIAL VACCINES, Bulletin of Problems Biology and Medicine, 1.1, 142, 2018. Crossref

  12. Beikzadeh Babak, Nikbakht Brujeni Gholamreza, Protection against neonatal enteric colibacillosis employing E. Coli-derived outer membrane vesicles in formulation and without vitamin D3, BMC Research Notes, 11, 1, 2018. Crossref

  13. Qi Xingmei, Lu Qian, Hu JingPing, Xiong Sidong, Spontaneous C-cleavage of a truncated intein as fusion tag to produce tag-free VP1 inclusion body nanoparticle vaccine against CVB3-induced viral myocarditis by the oral route, Microbial Cell Factories, 18, 1, 2019. Crossref

  14. Singh Santosh Kumar, Singh Rajesh, Estrogen Signaling Based Current and Potential Therapies Against Obesity and Related Diseases, in Obesity and Cancer, 2021. Crossref

  15. Elezaby Reham S., Nasr Maha, El-Sherbiny Ibrahim M., Mucosal vaccination through chitosan-based delivery systems, in Chitosan in Biomedical Applications, 2022. Crossref

  16. Correa Victor Araujo, Portilho Amanda Izeli, De Gaspari Elizabeth, Vaccines, adjuvants and key factors for mucosal immune response, Immunology, 167, 2, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain